Clinical Trial Update: Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 [Phase 2]

View source ↗

Summary

Pfizer conducted an open-label extension to evaluate the long-term safety, tolerability, and efficacy of Pf-02545920 in Huntington's disease patients who comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• PF-02545920

Snippet

Sponsor: Pfizer | Conditions: Huntington's Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-04-23